SynthesisMycoses2026
Insights Into the Susceptibility of Fungal Infection and STAT3 Genetic Mutations.
Synthesis in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Signal transducer and activator of transcription 3 (STAT3) is a key transcription factor that regulates a spectrum of genes and signalling pathways critical for the antifungal immune response. Mutations in the STAT3 gene confer susceptibility to severe and recurrent fungal infections, predominantly via disruption of interleukin-17 (IL-17)-mediated immunity. This review synthesises current mechanistic insights into STAT3 dysfunction, which impairs the differentiation and effector function of T helper 17 (Th17) cells. This defect results in a profound deficiency of IL-17 and IL-22, which are indispensable for orchestrating antifungal defence at mucosal barriers. The subsequent immunopathological features include impaired neutrophil recruitment to fungal invasion sites, compromised epithelial barrier function and failure to eradicate pathogens such as Candida spp. and Aspergillus spp. Consequently, individuals harbouring STAT3 mutations face a substantially increased risk of disseminated and chronic fungal diseases. Elucidating this STAT3-dependent signalling pathway is essential for deciphering the pathological basis of fungal susceptibility across diverse clinical settings and informing the development of targeted immunotherapies, including immunomodulatory and genetic therapeutic strategies. Additionally, we performed a systematic review of 135 published cases linking STAT3 mutations to fungal infections, aiming to further characterise the role of STAT3 gene defects in fungal susceptibility.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.